FBP1, Blocking Peptide

For Research Use Only. Not for use in diagnostic procedures.

Lyophilized powder

Add 100ul of sterile PBS. Final peptide concentration is 1 mg/ml in PBS. For longer periods of storage, store at -20 degree C. Avoid repeat freeze-thaw cycles.

Small volumes of FBP1 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Fructose-1,6-bisphosphatase 1, a gluconeogenesis regulatory enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate and inorganic phosphate. Fructose-1,6-diphosphatase deficiency is associated with hypoglycemia and metabolic acidosis.

Peptide

37kDa

fructose-bisphosphatase 1

fructose-1,6-bisphosphatase 1

Fructose-1,6-bisphosphatase 1

FBP; FBPase 1  [Similar Products]

F16P1_HUMAN

Fructose-1,6-bisphosphatase 1, a gluconeogenesis regulatory enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate and inorganic phosphate. Fructose-1,6-diphosphatase deficiency is associated with hypoglycemia and metabolic acidosis. [provided by RefSeq, Jul 2008]

FBPase: a key enzyme of gluconeogenesis that catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate, a precursor to glucose 6-phosphate. A regulator of glucose synthesis from non-carbohydrates. Two paralogs of this enzyme exists in humans, FBP1 in the liver and FBP2 in muscle. While both forms are inhibited allosterically by AMP, NAD and Ca2+, the muscle form is about 100-fold more sensitive to AMP and NAD, and about 1000-fold more sensitive to inhibition by Ca2+. Forms homotetramers that are stabilized in the active state by divalent cations (Mg2+, Mn2+ , Co+2, or Zn2+). Deficiency of FBP1 leads to a disorder mainly in the liver and causes life-threatening episodes of hypoglycemia and metabolic acidosis (lactacidemia) in newborn infants or young children.

Protein type: Carbohydrate Metabolism - glycolysis and gluconeogenesis; Phosphatase (non-protein); EC 3.1.3.11; Mitochondrial; Carbohydrate Metabolism - pentose phosphate pathway; Carbohydrate Metabolism - fructose and mannose

Chromosomal Location of Human Ortholog: 9q22.3

Cellular Component: cytoplasm; cytosol

Molecular Function: monosaccharide binding; identical protein binding; protein binding; metal ion binding; fructose-bisphosphatase activity; AMP binding

Biological Process: dephosphorylation; carbohydrate metabolic process; glucose metabolic process; negative regulation of Ras protein signal transduction; regulation of gluconeogenesis; pathogenesis; negative regulation of cell growth; fructose 6-phosphate metabolic process; negative regulation of glycolysis; fructose metabolic process; protein homotetramerization; gluconeogenesis

Disease: Fructose-1,6-bisphosphatase Deficiency

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.